Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
http://link.springer.com/content/pdf/10.1007/s10147-015-0799-2.pdf
Reference15 articles.
1. Giordano SH, Buzdar AU, Smith TL, et al (2004) Is breast cancer survival improving? Cancer 100(1):44–52
2. Saad ED, Katz A, Buyse M (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 28(11):1958–1962
3. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101(23):1642–1649
4. Saji S (2013) Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane. BioDrugs 27(5):469–478
5. Shien T, Nakamura K, Shibata T et al (2012) A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol 42(10):970–973
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer;International Journal of Clinical Oncology;2023-07-10
2. OCT1 Is a Poor Prognostic Factor for Breast Cancer Patients and Promotes Cell Proliferation via Inducing NCAPH;International Journal of Molecular Sciences;2021-10-25
3. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy;Journal of Hematology & Oncology;2019-12
4. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy;Current Pharmaceutical Design;2019-06-12
5. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation;Current Pharmaceutical Design;2017-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3